Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway-Reference-Cited by-同舟云学术

Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway

Published:2024-01-01 Issue:1 Volume:19 Page:
ISSN:2391-5463
Container-title:Open Medicine
language:en
Short-container-title:

Author:

Tan Chujun¹,Chen Junqiu²,Tu Tengcan¹,Chen Lifang³,Zou Jun¹⁴

Affiliation:

1. The Second School of Clinical Medicine, Southern Medical University , Guangzhou , 510280 , China

2. Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, (Shenzhen Sun Yat-sen Cardiovascular Hospital) , Shenzhen , 518057 , China

3. Department of Cardiology, Shenzhen Qianhai Shekou Free Trade Zone Hospital , Shenzhen , 528200 , China

4. Department of Cardiology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology , Foshan , 528200 , China

Abstract

Abstract The malfunction of endothelial progenitor cells (EPCs) due to ox-LDL is a risk contributor for arteriosclerotic disease. Meanwhile, lycopene possesses anti-inflammatory and antioxidative qualities. This investigation aimed to determine if lycopene can protect EPCs from ox-LDL-induced damage and to elucidate the underlying mechanism. The effects of lycopene on the survival, migration, and tube-forming capacity of EPCs were determined via in vitro assays. Expression of proteins related to pyroptosis and cellular proteins related to AMPK/mTOR/NLRP3 signaling was determined by western blot/flow cytometry. Our results demonstrated that lycopene treatment significantly enhanced proliferation, tube formation, and migration of EPCs stimulated by ox-LDL. Additionally, lycopene was found to suppress pyroptosis in ox-LDL-induced EPCs through the activation of AMPK, which led to the inhibition of mTOR phosphorylation and subsequent downregulation of the downstream NLRP3 inflammasome. In summary, our study suggests that lycopene mitigates ox-LDL-induced dysfunction in EPCs and inhibits pyroptosis via AMPK/mTOR/NLRP3 signaling. Our study suggests that lycopene may act as promising therapies for preventing atherosclerosis.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/med-2024-0973/pdf

Reference47 articles.

1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74(10):1376–414.

2. Shapiro MD, Bhatt DL. “Cholesterol-Years” for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76(13):1517–20.

3. Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, et al. Overview of OxLDL and its impact on cardiovascular health: Focus on atherosclerosis. Front Pharmacol. 2020;11:613780.

4. Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev. 2020;2020:5245308.

5. Qian W, Cai X, Qian Q, Zhuang Q, Yang W, Zhang X, et al. Astragaloside IV protects endothelial progenitor cells from the damage of ox-LDL via the LOX-1/NLRP3 inflammasome pathway. Drug Des Dev Ther. 2019;13:2579–89.